VYMETALOVA, Ladislava, Tereza KUCIRKOVA, Lucia KNOPFOVA, Veronika POSPISILOVA, Tomas KASKO, Hana LEJDAROVA, Eva MAKATUROVA, Petr KUGLÍK, Veronika ORALOVA, Eva MATALOVA, Petr BENES, Zdenek KORISTEK a Serhiy FOROSTYAK. Large-Scale Automated Hollow-Fiber Bioreactor Expansion of Umbilical Cord-Derived Human Mesenchymal Stromal Cells for Neurological Disorders. Neurochemical Research. New York: Springer, 2020, roč. 45, č. 1, s. 204-214. ISSN 0364-3190. Dostupné z: https://dx.doi.org/10.1007/s11064-019-02925-y.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Large-Scale Automated Hollow-Fiber Bioreactor Expansion of Umbilical Cord-Derived Human Mesenchymal Stromal Cells for Neurological Disorders
Autoři VYMETALOVA, Ladislava, Tereza KUCIRKOVA, Lucia KNOPFOVA, Veronika POSPISILOVA, Tomas KASKO, Hana LEJDAROVA, Eva MAKATUROVA, Petr KUGLÍK (203 Česká republika, garant, domácí), Veronika ORALOVA, Eva MATALOVA, Petr BENES, Zdenek KORISTEK a Serhiy FOROSTYAK.
Vydání Neurochemical Research, New York, Springer, 2020, 0364-3190.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10608 Biochemistry and molecular biology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.996
Kód RIV RIV/00216224:14310/20:00117084
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1007/s11064-019-02925-y
UT WoS 000511696200018
Klíčová slova anglicky Mesenchymal stromal cells; Umbilical cord tissue; Bioreactor; Large-scale expansion; Good manufacturing practice (GMP)
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 25. 11. 2020 13:27.
Anotace
Neurodegenerative disorders present a broad group of neurological diseases and remain one of the greatest challenges and burdens to mankind. Maladies like amyotrophic lateral sclerosis, Alzheimer's disease, stroke or spinal cord injury commonly features astroglia involvement (astrogliosis) with signs of inflammation. Regenerative, paracrine and immunomodulatory properties of human mesenchymal stromal cells (hMSCs) could target the above components, thus opening new therapeutic possibilities for regenerative medicine. A special interest should be given to hMSCs derived from the umbilical cord (UC) tissue, due to their origin, properties and lack of ethical paradigms. The aim of this study was to establish standard operating and scale-up good manufacturing practice (GMP) protocols of UC-hMSCs isolation, characterization, expansion and comparison of cells' properties when harvested on T-flasks versus using a large-scale bioreactor system. Human UC-hMSCs, isolated by tissue explant culture technique from Wharton's jelly, were harvested after reaching 75% confluence and cultured using tissue culture flasks. Obtained UC-hMSCs prior/after the cryopreservation and after harvesting in a bioreactor, were fully characterized for "mesenchymness" immunomodulatory, tumorigenicity and genetic stability, senescence and cell-doubling properties, as well as gene expression features. Our study demonstrates an efficient and simple technique for large scale UC-hMSCs expansion. Harvesting of UC-hMSCs' using classic and large scale methods did not alter UC-hMSCs' senescence, genetic stability or in vitro tumorigenicity features. We observed comparable growth and immunomodulatory capacities of fresh, frozen and expanded UC-hMSCs. We found no difference in the ability to differentiate toward adipogenic, osteogenic and chondrogenic lineages between classic and large scale UC-hMSCs expansion methods. Both, methods enabled derivation of genetically stabile cells with typical mesenchymal features. Interestingly, we found significantly increased mRNA expression levels of neural growth factor (NGF) and downregulated insulin growth factor (IGF) in UC-hMSCs cultured in bioreactor, while IL4, IL6, IL8, TGFb and VEGF expression levels remained at the similar levels. A culturing of UC-hMSCs using a large-scale automated closed bioreactor expansion system under the GMP conditions does not alter basic "mesenchymal" features and quality of the cells. Our study has been designed to pave a road toward translation of basic research data known about human UC-MSCs for the future clinical testing in patients with neurological and immunocompromised disorders. An industrial manufacturing of UC-hMSCs next will undergo regulatory approval following advanced therapy medicinal products (ATMP) criteria prior to clinical application and approval to be used in patients.
VytisknoutZobrazeno: 26. 4. 2024 17:38